# EDGAR Filing Document

**Accession Number:** 0001610853
**File Stem:** 0001104659-25-113672
**Filing Date:** 2025-11
**Character Count:** 18141
**Document Hash:** 3c9e92e8b12f610722d1c2b98b600050
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-113672.hdr.sgml**: 20251118

**ACCESSION NUMBER**: 0001104659-25-113672

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251118

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251118

**DATE AS OF CHANGE**: 20251118

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Solana Co
- **CENTRAL INDEX KEY:** 0001610853
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 364787690
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38445
- **FILM NUMBER:** 251494973

**BUSINESS ADDRESS:**
- **STREET 1:** 642 NEWTOWN YARDLEY ROAD
- **CITY:** NEWTOWN
- **STATE:** PA
- **ZIP:** 18940
- **BUSINESS PHONE:** 215-944-6100

**MAIL ADDRESS:**
- **STREET 1:** 642 NEWTOWN YARDLEY ROAD
- **CITY:** NEWTOWN
- **STATE:** PA
- **ZIP:** 18940

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HELIUS MEDICAL TECHNOLOGIES, INC.
- **DATE OF NAME CHANGE:** 20180525

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HELIUS MEDICAL TECHNOLOGIES, INC
- **DATE OF NAME CHANGE:** 20180517

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HELIUS MEDICAL TECHNOLOGIES, INC.
- **DATE OF NAME CHANGE:** 20140613

?xml version='1.0' encoding='ASCII'? SOLANA COMPANY_November 18, 2025

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 18, 2025**

![Graphic](hsdt-20251118x8k001.jpg)

## SOLANA COMPANY
**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| -<br>|  |  |
| **Delaware** | **001-38445** | **36-4787690** |
| **(State or other jurisdiction**<br>**of incorporation)** | **(Commission File Number)** | **(IRS Employer**<br>**Identification No.)** |
| **642 Newtown Yardley Road, Suite 100**<br>**Newtown, PA** |  | **18940** |
| **(Address of principal executive offices)** |  | **(Zip Code)** |

---

**Registrant's telephone number, including area code: (215) 944-6100**

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange on which registered** |
| Class A Common Stock, $0.001 par value | HSDT | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02** **Results of Operations and Financial Condition.**

On November 18, 2025, Solana Company (formerly known as Helius Medical Technologies, Inc.) (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2025, a business update, and information regarding a conference call to discuss these financial results and recent corporate highlights. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference.

The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

 **(d) Exhibits**

---

| | |
|:---|:---|
| Exhibit No.  | Description  |
| 99.1 | [Press Release dated November 18, 2025](hsdt-20251118xex99d1.htm). |
| 104 | Cover Page Interactive Data File (embedded within Inline XBRL document). |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **SOLANA COMPANY.** | **SOLANA COMPANY.** |
| Dated: November 18, 2025 | By: | /s/ Jeffrey S. Mathiesen |
|  |  | Jeffrey S. Mathiesen |
|  |  | Chief Financial Officer, Treasurer and Secretary |

---

## Exhibit 99.1

**Exhibit 99.1**

**Solana Company Reports Third Quarter 2025 Financial Results**

NEWTOWN, Pa., Nov. 18, 2025 (GLOBE NEWSWIRE) *--* Solana Company (NASDAQ: HSDT) (the "Company" or "HSDT"), a publicly listed company that has expanded its business to include a digital asset treasury ("DAT") dedicated to acquiring and holding Solana tokens ("SOL"), today announced results for the quarter ended September 30, 2025.

**Third Quarter and Recent Business Updates** 

● Closed partnership with Pantera Capital and Summer Capital of over $500 Million in funding in cash and stablecoins to launch SOL treasury strategy

● Issued cash-exercise warrants, allowing for a potential aggregate $750M additional capital raise for the Company

● Launched ATM program, giving the company flexibility to raise additional capital

● Approved a stock repurchase program to acquire up to $100 million of the company's outstanding common stock

● Announced positive clinical data which demonstrated PoNS superior effectiveness in improving gait deficit by achieving a clinically meaningful mean improvement compared to the control group, reflecting the clinical significance of this therapeutic intervention

● Submitted FDA 510(k) designation for PoNS® Device Label Expansion in Stroke

"Solana Company's digital treasury strategy and the recent PIPE transaction are significant milestones for the Company and its shareholders. With the added commitment and support of Pantera and Summer, we believe that we are positioned well to accelerate growth and drive value. Since closing, we have achieved notable progress across our three core execution pillars: advocacy, capital markets, and treasury management," said Joseph Chee, Executive Chairman. "I'm proud of the continued expansion in adoption as the Solana network has become the world's most widely used and economically productive blockchain. Our recent ATM launch and issuance of cash-exercise warrants have strengthened our financial position and prepared us to scale effectively. These initiatives position Solana for sustained growth and long-term success within the DAT landscape."

**Third Quarter 2025 Financial Results** 

Our financial results include the $508 million PIPE transaction that closed on September 18, 2025 and related DAT activities from that date through the end of the quarter.

Our third quarter revenue of $697,000 included first-time staking rewards income of $342,000.

For the third quarter, cost of revenue was $103,000 compared to $187,000 for the prior-year period, mainly due to decreased inventory reserve and production scrap expenses.

Selling, general and administrative expenses for the third quarter of 2025 were $4.6 million compared to the $2.9 million for the prior year period, with the increase comprised of a $1.5 million discretionary bonus in the current year. Research and development expenses for the third quarter of 2025 were $0.9 million compared to $1.1 million for the prior year period, driven primarily by reduced clinical trial activities. An unrealized loss on digital assets of $30.5 million resulted from the net change in fair value of digital assets held by the Company as of quarter end.

Total operating expenses for the third quarter of 2025 were $36.0 million, compared to $3.9 million in the prior year period.

60878657.2 ------

The resulting loss from operations for the third quarter of 2025 was $35.5 million compared to a loss of $4.1 million for the prior-year period.

Current year non-operating loss in the third quarter of $317.3 million included a $545.7 million loss on derivative liability attributable to the valuation of the stapled warrants from the September PIPE transaction and $194.7 million of financing costs from the September PIPE transaction including a $171.3 million non-cash charge from the advisory warrants issued and $8.6 million non-cash charge for shares issued to Clear Street, offset by a $423.3 million gain from the change in fair value of the related derivative liability from those stapled warrants, which comprise the changes from the prior year period.

We reported a net loss for the third quarter of 2025 of $352.8 million or a loss of $32.89 per basic and diluted common share compared to a net loss of $3.7 million in the prior-year period or a loss of $744.35 per basic and diluted common share.

**Cash and Liquidity** 

At September 30, 2025 we had $124 million in cash and $350.2 million of digital assets at fair value, for a combined total of $474.2 million. Also at that date, we had a combined total of 75.9 million common shares and pre-funded warrants outstanding.

**Conference Call** 

Management will host a conference call to discuss the results and provide an expanded business update as follows:

---

| | |
|:---|:---|
| &nbsp;&nbsp;Date: | &nbsp;&nbsp;Tuesday, November 18, 2025  |
| &nbsp;&nbsp;Time: | &nbsp;&nbsp;4:30 p.m. Eastern Time |
| &nbsp;&nbsp;Webcast:  | &nbsp;&nbsp;**Click here** |

---

The webcast will be archived under the News & Events section of the Company's investor relations website.

**About Solana Company**

Solana Company (NASDAQ: HSDT) is a leading neurotech company in the medical device field focused on neurologic deficits using orally applied technology platform that amplifies the brain's ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. It is also a listed digital asset treasury ("DAT") dedicated to acquiring and holding Solana (SOL). Created in partnership with Pantera Capital and Summer Capital, Solana Company's DAT objective is to maximize SOL per share through strategic use of capital markets and on chain opportunities, offering public market investors direct exposure to Solana's secular growth.

For more information, please visit www.solanacompany.co or follow us on X (@Solana_Company).

**Forward Looking Statements**<br> This press release contains statements that constitute "forward-looking statements" within the meaning of the U.S. federal securities laws. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "intend", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms or other comparable terminology. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Forward-

------

looking statements may include, among others, statements in relation to the Company's future growth and operational progress, the Company's execution of its Solana digital asset treasury strategy and the potential opportunities such initiatives may create , expected enrollment, developments and future plans regarding regulatory entities, receipt of prescriptions and progress of commercialization of the PoNS device in the U.S., the impacts of the current global macroeconomic environment on the Company, product development activities, the safety and effectiveness of the Company's product, the manufacturing plans for the Company's product, sufficiency of cash and availability of funds and operating costs and the Company's ability to continue as a going concern and future liquidity.

These forward-looking statements are based on current expectations, estimates, assumptions, and projections, and involve known and unknown risks, uncertainties, and other factors-many of which are beyond the Company's control-that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. Important factors that may affect actual results include, among others, the Company's ability to execute its growth strategy; its ability to raise and deploy capital effectively; developments in technology and the competitive landscape; the market performance of SOL; and other risks and uncertainties described under "Risk Factors" in the Company's Annual Report on Form 10-K filed with the United States Securities and Exchange Commission ("SEC") on March 25, 2025, and in other subsequent filings with the SEC. These filings are available at www.sec.gov. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

**Media Contacts:**

<u>Solana Company</u> <u><u>ir@solanacompany.co</u></u> <br> <u>Pantera Capital Management LP</u> <u><u>ir@panteracapital.com</u></u> <br> Summer Capital Limited <u>pr@summer-cap.com</u>

------

**Solana Company**

**Unaudited Condensed Consolidated Balance Sheets**

(in thousands, except share data)

---

| | | |
|:---|:---|:---|
|  | **September 30, 2025** | **December 31, 2024** |
| **ASSETS** |  |  |
| **Current assets** |  |  |
| &nbsp;&nbsp;Cash and cash equivalents | $124051 | $1088 |
| &nbsp;&nbsp;Inventory | 1128 | 1036 |
| &nbsp;&nbsp;Prepaid expenses and other current assets | 484 | 1300 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 125663 | 3424 |
| Digital assets, at fair value | 291078 |  |
| Digital assets, restricted, at fair value | 59097 |  |
| Other long-term assets | 82 | 118 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total assets | $475920 | $3542 |
| **LIABILITIES AND STOCKHOLDERS' EQUITY** |  |  |
| **Current liabilities** |  |  |
| &nbsp;&nbsp;Accounts payable | $2485 | $873 |
| &nbsp;&nbsp;Accrued and other current liabilities | 654 | 1290 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 3139 | 2163 |
| Other long-term liabilities |  | 79 |
| Derivative liability | 625173 | 241 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 628312 | 2483 |
| **Stockholders' (deficit) equity** |  |  |
| &nbsp;&nbsp;Class A common stock, $0.001 par value; 800,000,000 shares authorized; 40,299,228 and 4,936 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | 40 |  |
| &nbsp;&nbsp;Additional paid-in capital | 385768 | 172425 |
| &nbsp;&nbsp;Accumulated deficit | (538140) | (171699) |
| &nbsp;&nbsp;Accumulated other comprehensive (loss) income | (60) | 333 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' (deficit) equity | (152392) | 1059 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $475920 | $3542 |

---

------

**Solana Company**

**Unaudited Condensed Consolidated Statements of Operations**

(in thousands, except share and per share data)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended**  | **Three Months Ended**  | **Nine Months Ended**  | **Nine Months Ended**  |
|  | **September 30,**  | **September 30,**  | **September 30,**  | **September 30,**  |
|  | **2025** | **2024** | **2025** | **2024** |
| **Revenue** |  |  |  |  |
| &nbsp;&nbsp;Staking rewards | $342 | $— | $342 | $— |
| &nbsp;&nbsp;Other revenue | 355 | 51 | 447 | 368 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total revenue | 697 | 51 | 789 | 368 |
| Cost of revenue | 103 | 187 | 320 | 428 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross profit (loss) | 594 | (136) | 469 | (60) |
| **Operating expenses** |  |  |  |  |
| &nbsp;&nbsp;Selling, general and administrative expenses | 4646 | 2857 | 10089 | 7961 |
| &nbsp;&nbsp;Research and development expenses | 858 | 1077 | 2625 | 2735 |
| &nbsp;&nbsp;Unrealized loss on digital assets | 30540 |  | 30540 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 36044 | 3934 | 43254 | 10696 |
| Loss from operations | (35450) | (4070) | (42785) | (10756) |
| **Nonoperating income** |  |  |  |  |
| &nbsp;&nbsp;Interest expense | (1) | (1) | (635) | (14) |
| &nbsp;&nbsp;Other (expense) income | (154) | 233 | 503 | (71) |
| &nbsp;&nbsp;Loss on derivative liability | (545733) |  | (545733) |  |
| &nbsp;&nbsp;Change in fair value of derivative liability | 423313 | 152 | 417394 | 3027 |
| &nbsp;&nbsp;Financing costs | (194743) |  | (195185) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Nonoperating (loss) income, net | (317318) | 384 | (323656) | 2942 |
| Loss before provision for income taxes | (352768) | (3686) | (366441) | (7814) |
| Provision for income taxes |  |  |  |  |
| Net loss | $(352768) | $(3686) | $(366441) | $(7814) |
| **Loss per share** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic and diluted | $(32.89) | $(744.35) | $(90.14) | $(2507.81) |
| **Weighted average number of common shares outstanding** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic and diluted | 10724112 | 4952 | 4065144 | 3116 |

---

------